title: Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.
abstract: In patients with non-small-cell lung cancer harboring an epithelial growth factor receptor (EGFR) active mutation, central nervous system progression after a response to EGFR tyrosine kinase inhibitors is frequent. Central nervous system metastasis, especially leptomeningeal carcinomatosis (LMC), is a serious complication and no standard treatment has been established for LMC. Here, we report two cases in which the addition of bevacizumab to erlotinib enhanced the efficacy against LMC; as a result, radiographic abnormalities decreased markedly and symptoms were well controlled. This combination treatment may be useful to treat LMC in patients with EGFR-positive non-small-cell lung cancer.
authors.affiliation: Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
authors.forename: Ryo
authors.initials: R
authors.lastname: Ariyasu
authors.forename: Atsushi
authors.initials: A
authors.lastname: Horiike
authors.forename: Junji
authors.initials: J
authors.lastname: Koyama
authors.forename: Masafumi
authors.initials: M
authors.lastname: Saiki
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Sonoda
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kawashima
authors.forename: Natsuki
authors.initials: N
authors.lastname: Takano
authors.forename: Tomoyo
authors.initials: T
authors.lastname: Oguri
authors.forename: Shingo
authors.initials: S
authors.lastname: Nishikawa
authors.forename: Satoru
authors.initials: S
authors.lastname: Kitazono
authors.forename: Noriko
authors.initials: N
authors.lastname: Yanagitani
authors.forename: Fumiyoshi
authors.initials: F
authors.lastname: Ohyanagi
authors.forename: Makoto
authors.initials: M
authors.lastname: Nishio
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D055756:Meningeal Carcinomatosis / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D017211:Treatment Failure
chemical_list: D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride